Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Bullboard Posts
Comment by Bigmac4000on Jun 12, 2020 11:08pm
73 Views
Post# 31145975

RE:Look at it

RE:Look at itYou posted the exact same yesterday and even highlighted it all lol. So I'll say again, the patent is 2030 and FSD won't be done testing till 2021 at earliest. That leaves less than 9 years on patent. Secondly who cares what the investors could do. It's 10.1 million until they do more. Not 20 or any other made up number. 10.1. Yes they sold cannara for 7.7 mill and at end of March 31 has 8 million total in bank. Going by their financials they should have around 14-15 million right now. That's it. They don't have 20 million and they haven't sold the building but they are paying for it, and it's not cheap. They have enough money to get them into 2021 after that we shall see. Those are facts not highlighted guesses and hopes. Nice on the new accounts though. Can hardly tell it's the same person.
EGEGELGELGEL123 wrote: 10 Million Dollar raise created some dilution but they need it to advance their efforts pharma business isn’t free and is costly things take time and most importantly money. We have been given a life force with that 10 million, keep in mind those institutional investors have an option of investing an additional $10,000,000 on top of the first private placement. So that is like almost 20,000,000, the FSD pharma facility isn’t sold yet and that would have been another 19 million. They sold cannara for 8 million. Hopefully that is enough to pay for phase 1 in Australia the new have phase 2 costs.


Bullboard Posts